These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 11459172)
1. Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes. Mazzocchi A; Melani C; Rivoltini L; Castelli C; Del Vecchio M; Lombardo C; Colombo MP; Parmiani G Cancer Immunol Immunother; 2001 Jun; 50(4):199-211. PubMed ID: 11459172 [TBL] [Abstract][Full Text] [Related]
3. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients. Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871 [TBL] [Abstract][Full Text] [Related]
4. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines. Fenton RG; Turcovski-Corrales SM; Taub DD J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360 [TBL] [Abstract][Full Text] [Related]
5. Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine. Shawler DL; Bartholomew RM; Garrett MA; Trauger RJ; Dorigo O; Van Beveren C; Marchese A; Ferre F; Duffy C; Carlo DJ; Sherman LA; Gold DP; Sobol RE Clin Exp Immunol; 2002 Jul; 129(1):99-106. PubMed ID: 12100028 [TBL] [Abstract][Full Text] [Related]
6. Transfection of IL-2 augments CTL response to human melanoma cells in vitro: immunological characterization of a melanoma vaccine. van Elsas A; Aarnoudse C; van der Minne CE; van der Spek CW; Brouwenstijn N; Osanto S; Schrier PI J Immunother; 1997 Sep; 20(5):343-53. PubMed ID: 9336741 [TBL] [Abstract][Full Text] [Related]
7. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302 [TBL] [Abstract][Full Text] [Related]
8. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Arienti F; Sulé-Suso J; Belli F; Mascheroni L; Rivoltini L; Melani C; Maio M; Cascinelli N; Colombo MP; Parmiani G Hum Gene Ther; 1996 Oct; 7(16):1955-63. PubMed ID: 8930655 [TBL] [Abstract][Full Text] [Related]
9. Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class I-matched allogeneic peripheral blood lymphocytes by B7 gene-modified melanoma cells. Yang S; Darrow TL; Seigler HF Cancer Res; 1997 Apr; 57(8):1561-8. PubMed ID: 9108460 [TBL] [Abstract][Full Text] [Related]
10. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells. Dezfouli S; Hatzinisiriou I; Ralph SJ Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen. Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334 [TBL] [Abstract][Full Text] [Related]
12. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Slingluff CL; Colella TA; Thompson L; Graham DD; Skipper JC; Caldwell J; Brinckerhoff L; Kittlesen DJ; Deacon DH; Oei C; Harthun NL; Huczko EL; Hunt DF; Darrow TL; Engelhard VH Cancer Immunol Immunother; 2000 Mar; 48(12):661-72. PubMed ID: 10752474 [TBL] [Abstract][Full Text] [Related]
13. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316 [TBL] [Abstract][Full Text] [Related]
14. IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response. Guarini A; Gansbacher B; Cronin K; Fierro MT; Foa R Cytokines Mol Ther; 1995 Mar; 1(1):57-64. PubMed ID: 9384664 [TBL] [Abstract][Full Text] [Related]
15. Restoration of alloreactivity of melanoma by transduction with B7.1. Brady MS; Lee F; Eckels DD; Ree SY; Latouche JB; Lee JS J Immunother; 2000; 23(3):353-61. PubMed ID: 10838664 [TBL] [Abstract][Full Text] [Related]
16. Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells: suppression by interleukin 10. Dummer R; Yue FY; Pavlovic J; Geertsen R; Döhring C; Moelling K; Burg G Br J Cancer; 1998 May; 77(9):1413-9. PubMed ID: 9652756 [TBL] [Abstract][Full Text] [Related]
17. Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro. Imro MA; Dellabona P; Manici S; Heltai S; Consogno G; Bellone M; Rugarli C; Protti MP Hum Gene Ther; 1998 Jun; 9(9):1335-44. PubMed ID: 9650618 [TBL] [Abstract][Full Text] [Related]
18. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. Tüting T; Wilson CC; Martin DM; Kasamon YL; Rowles J; Ma DI; Slingluff CL; Wagner SN; van der Bruggen P; Baar J; Lotze MT; Storkus WJ J Immunol; 1998 Feb; 160(3):1139-47. PubMed ID: 9570527 [TBL] [Abstract][Full Text] [Related]
20. Generation of Melan-A/MART-1-specific CD8+ cytotoxic T lymphocytes from human naive precursors: helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro. Ostankovitch M; Le Gal FA; Connan F; Chassin D; Choppin J; Guillet JG Int J Cancer; 1997 Sep; 72(6):987-94. PubMed ID: 9378563 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]